Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Revlimid Dose 25 mg in Association With (R-CHOP) in the Treatment Follicular Lymphoma (R2-CHOP2)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Centre Henri Becquerel
Information provided by (Responsible Party):
The Lymphoma Academic Research Organisation
ClinicalTrials.gov Identifier:
NCT01393756
First received: July 4, 2011
Last updated: December 23, 2014
Last verified: December 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: July 2015
  Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)